Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib + MEC for Relapsed/Refractory c-kit+ AML
NCT01126814Phase 2Completed
- Sponsor
- University Health Network
- Start
- Jul 2004
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in acute myeloid leukemia (AML), sponsored by University Health Network. Primary endpoints: Toxicity of Imatinib and Chemotherapy at 2 years, Response Rate (CR, MLFS, PR) at 2 years and 1 more. Started Jul 2004; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01126814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01126814.